Local view for "https://dbmi-icode-01.dbmi.pitt.edu/dikb/resource/Evidence/458"
| Predicate | Value (sorted: default) |
|---|---|
| rdfs:label | |
| rdf:type | |
| ?:Evidence_enzyme_system | |
| ?:Evidence_numb_subjects | |
| ?:Evidence_object_dose | |
| ?:Evidence_precip_dose | |
| ?:Evidence_type | |
| ?:content |
"Route of administration: oral
study duration: 2 days treatment w/ triazolam (TRZ) alone (.25mg 1xday) followed by 7 days treatment with nevazodone alone (200mg, bid); followed by two days dosing with nevazodone + TRZ
population: 12 male
ages:23-38
NOTE: this evidence supports that no interaction occurs when <= 2 doses of alprazolam are co-administered with nefazodone
"
Noncompartmental pharmacokinetic analysis showed that there was no effect of triazolam on the pharmacokinetics of nefazodone, HO-nefazodone, or mCPP after the coadministration of triazolam and nefazodone. There was a significant effect of 200 mg of nefazodone twice daily on the pharmacokinetics of triazolam.
""
|
| dc:creator | |
| dc:date |
"12/10/2007 16:03:18"
|
| rdfs:seeAlso |
All properties reside in the graph file:///home/swish/src/ClioPatria/guidelines/dikb.ttl
The resource appears as object in one triple:
{ triazolam_increases_auc_nefazodone, <http://purl.org/swan/1.2/swan-commons#citesAsRefutingEvidence>, evidence_1625 }